Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBITDA (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EBITDA for 9 consecutive years, with -$129.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 9.05% to -$129.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$513.9 million through Dec 2025, down 21.95% year-over-year, with the annual reading at -$513.9 million for FY2025, 21.95% down from the prior year.
  • EBITDA for Q4 2025 was -$129.0 million at Denali Therapeutics, down from -$126.7 million in the prior quarter.
  • The five-year high for EBITDA was $184.5 million in Q2 2023, with the low at -$133.0 million in Q1 2025.
  • Average EBITDA over 5 years is -$84.8 million, with a median of -$99.7 million recorded in 2024.
  • The sharpest move saw EBITDA skyrocketed 398.4% in 2023, then crashed 154.42% in 2024.
  • Over 5 years, EBITDA stood at -$77.2 million in 2021, then dropped by 21.33% to -$93.7 million in 2022, then decreased by 26.11% to -$118.2 million in 2023, then decreased by 0.07% to -$118.3 million in 2024, then dropped by 9.05% to -$129.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$129.0 million, -$126.7 million, and -$125.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.